Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNYSE:ANTMNYSE:JNJNYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$206.08-1.6%$198.94$153.58▼$218.66$370.64B0.615.72 million shs7.85 million shsANTMAnthem$0.00$355.43▼$533.68$116.34BN/A1.21 million shs1.27 million shsJNJJohnson & Johnson$153.25-7.6%$159.16$140.68▼$169.99$369.30B0.477.69 million shs23.29 million shsNVONovo Nordisk A/S$68.00-2.1%$81.89$66.81▼$148.15$305.16B0.425.56 million shs6.21 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-1.79%+2.47%-1.43%+15.97%+14.04%ANTMAnthem0.00%0.00%0.00%0.00%0.00%JNJJohnson & Johnson-7.62%-4.90%-7.25%+5.96%-2.87%NVONovo Nordisk A/S-2.27%-7.57%-25.00%-20.95%-46.69%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.5241 of 5 stars2.53.03.33.93.52.51.3ANTMAnthemN/AN/AN/AN/AN/AN/AN/AN/AJNJJohnson & Johnson4.7527 of 5 stars3.33.04.23.92.62.51.3NVONovo Nordisk A/S4.8264 of 5 stars4.45.02.50.02.00.04.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.92Moderate Buy$211.452.61% UpsideANTMAnthem 0.00N/AN/AN/AJNJJohnson & Johnson 2.56Moderate Buy$171.3311.80% UpsideNVONovo Nordisk A/S 2.80Moderate Buy$145.25113.60% UpsideCurrent Analyst Ratings BreakdownLatest ANTM, JNJ, ABBV, and NVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025ABBVAbbVieErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/13/2025NVONovo Nordisk A/SKepler Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy3/10/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/5/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.003/5/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$159.00 ➝ $171.003/4/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.003/3/2025NVONovo Nordisk A/SStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold2/19/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.002/12/2025NVONovo Nordisk A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight2/3/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$205.00 ➝ $215.002/3/2025ABBVAbbVieTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $217.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.47$15.23 per share13.53$1.90 per share108.46ANTMAnthemN/AN/AN/AN/AN/AN/AJNJJohnson & Johnson$88.82B4.16$12.59 per share12.17$29.69 per share5.16NVONovo Nordisk A/S$290.40B1.05$3.15 per share21.57$4.64 per share14.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.4085.8714.741.627.59%296.28%12.65%4/25/2025 (Estimated)ANTMAnthemN/A$32.5414.83N/AN/AN/AN/AN/AN/AJNJJohnson & Johnson$14.07B$6.6523.0413.842.5618.20%34.24%13.63%4/15/2025 (Estimated)NVONovo Nordisk A/S$14.64B$3.2920.6714.590.9034.81%84.68%26.29%5/1/2025 (Estimated)Latest ANTM, JNJ, ABBV, and NVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/25/2025N/AABBVAbbVie$2.51N/AN/AN/A$12.91 billionN/A4/15/2025N/AJNJJohnson & Johnson$2.59N/AN/AN/A$21.65 billionN/A2/5/2025Q4 2024NVONovo Nordisk A/S$0.88$0.91+$0.03$0.91N/AN/A1/31/2025Q4 24ABBVAbbVie$2.98$2.16-$0.82-$0.02$14.81 billionN/A1/22/2025Q4 2024JNJJohnson & Johnson$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.18%+6.04%273.33%53 YearsANTMAnthem$5.121.06%N/A15.73%N/AJNJJohnson & Johnson$4.963.24%+5.43%74.59%63 YearsNVONovo Nordisk A/S$1.572.31%+25.26%47.72%N/ALatest ANTM, JNJ, ABBV, and NVO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025ABBVAbbViequarterly$1.643.4%4/15/20254/15/20255/15/20252/5/2025NVONovo Nordisk A/Ssemi-annual$0.78741.2%3/31/20253/31/20254/8/20251/2/2025JNJJohnson & Johnsonquarterly$1.243.43%2/18/20252/18/20253/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie17.940.660.55ANTMAnthemN/AN/AN/AJNJJohnson & Johnson0.431.110.86NVONovo Nordisk A/S0.620.740.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ANTMAnthemN/AJNJJohnson & Johnson69.55%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.08%ANTMAnthemN/AJNJJohnson & Johnson0.16%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie50,0001.77 billion1.76 billionOptionableANTMAnthemN/A241.09 millionN/AOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableNVONovo Nordisk A/S54,4004.49 billion4.48 billionOptionableANTM, JNJ, ABBV, and NVO HeadlinesRecent News About These CompaniesPotomac Fund Management Inc. ADV Makes New Investment in Novo Nordisk A/S (NYSE:NVO)April 2 at 6:17 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Stake Lifted by Nomura Asset Management Co. Ltd.April 2 at 4:11 AM | marketbeat.comCoffers swelling on Wegovy sales, Novo Holdings doubles income and returns in 2024April 2 at 1:32 AM | reuters.comFDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risksApril 1 at 7:43 PM | fiercepharma.comBarclays cuts Novo Nordisk estimates on lower Wegovy, Ozempic volumes in the U.S.April 1 at 7:43 PM | finance.yahoo.comNovo Nordisk A/S (NYSE:NVO) Trading Down 0% - Here's What HappenedApril 1 at 2:43 PM | marketbeat.comTrexquant Investment LP Purchases 62,267 Shares of Novo Nordisk A/S (NYSE:NVO)April 1 at 6:54 AM | marketbeat.comMay Hill Capital LLC Buys New Shares in Novo Nordisk A/S (NYSE:NVO)April 1 at 6:46 AM | marketbeat.comOLD Mission Capital LLC Acquires Shares of 503,079 Novo Nordisk A/S (NYSE:NVO)April 1 at 6:20 AM | marketbeat.comNemes Rush Group LLC Reduces Position in Novo Nordisk A/S (NYSE:NVO)April 1 at 6:10 AM | marketbeat.comCannell & Spears LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)April 1 at 5:42 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Sets New 1-Year Low - Time to Sell?April 1 at 4:11 AM | marketbeat.comNovo Nordisk’s Worst Month Since 2002 Highlights Growth ConcernsApril 1 at 12:35 AM | bloomberg.com1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss DrugApril 1 at 12:35 AM | benzinga.comNovo Nordisk Stock (NVO) Drops Despite Positive GLP-1 Trial DataApril 1 at 12:35 AM | markets.businessinsider.comNovo Nordisk A/S (NYSE:NVO) Stock Price Down 0.3% - Here's WhyMarch 31 at 2:45 PM | marketbeat.comWhich Healthcare Stock Is the Best Buy Right Now? (NVO)March 31 at 7:15 AM | marketbeat.comMeridian Investment Counsel Inc. Has $3.93 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)March 31 at 7:11 AM | marketbeat.comSaratoga Research & Investment Management Has $60.27 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)March 31 at 5:52 AM | marketbeat.comBlair William & Co. IL Sells 15,720 Shares of Novo Nordisk A/S (NYSE:NVO)March 31 at 4:23 AM | marketbeat.comNovo Nordisk: Finally A Buying OpportunityMarch 30 at 11:03 AM | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyAbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketBy Chris Markoch | March 23, 2025View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketDespite Challenges Novo Nordisk Plans to Crush GLP-1 CompetitorsBy Jea Yu | March 10, 2025View Despite Challenges Novo Nordisk Plans to Crush GLP-1 CompetitorsResilient Investing: 3 Stocks Built to Weather Market VolatilityBy Jeffrey Neal Johnson | March 17, 2025View Resilient Investing: 3 Stocks Built to Weather Market VolatilityANTM, JNJ, ABBV, and NVO Company DescriptionsAbbVie NYSE:ABBV$206.08 -3.44 (-1.64%) Closing price 04/1/2025 03:59 PM EasternExtended Trading$206.80 +0.72 (+0.35%) As of 06:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Anthem NYSE:ANTMElevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journeyconnecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.Johnson & Johnson NYSE:JNJ$153.24 -12.60 (-7.59%) Closing price 04/1/2025 03:59 PM EasternExtended Trading$153.25 +0.00 (+0.00%) As of 06:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novo Nordisk A/S NYSE:NVO$68.00 -1.44 (-2.07%) Closing price 04/1/2025 03:59 PM EasternExtended Trading$67.70 -0.30 (-0.44%) As of 06:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
